ADVENZYMES.NS Stock Analysis
AD
Avoid
Based on Eyestock quantitative analysis, ADVENZYMES.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
0.313
Dividend yield
1.62 %
Shares outstanding
111.82 B
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra and currently employs 338 full-time employees. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing, and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit, and vegetable processing, brewing, and malting, grain processing, protein modification, dairy processing, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase, and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather, and biofuels. Its oils and fats processing include oil extraction, oil refining, and others.